Close Menu

NEW YORK – Janssen Pharmaceutical said on Monday its investigational new drug amivantamab demonstrated activity and was well-tolerated in non-small cell lung cancer patients with EGFR exon 20 insertions in a Phase I trial.

CHRYSALIS is a Phase I, open-label trial evaluating the safety, pharmacokinetics, and efficacy of amivantamab as a monotherapy and in combination with lazertinib, a third-generation EGFR tyrosine kinase inhibitor Janssen is developing with Korean pharmaceutical company Yuhan. 

Get the full story with
Premium Access

Only $95 for the
first 90 days*

Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try Premium Access now.

You may already have institutional access!

Check if I qualify.

Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Sponsored by

The Phosphoinositide 3-Kinase (PI3K) pathway is one of the most frequently altered pathways in human cancer and plays a significant role in disease progression and resistance to endocrine therapy.